<DOC>
	<DOCNO>NCT02325180</DOCNO>
	<brief_summary>This prospective , open label , randomise control trial ass safety efficacy dihydroartemisinin-piperaquine artemether-lumefantrine child adult uncomplicated Plasmodium falciparum malaria infection . Molecular marker antimalarial resistance also assess presence molecular marker parasite associate treatment outcome .</brief_summary>
	<brief_title>Artemisinin-based Combination Therapy Treatment Plasmodium Falciparum Malaria North Sumatera , Indonesia</brief_title>
	<detailed_description>Artemisinin-based combination therapy ( ACT ) current recommend treatment WHO uncomplicated falciparum malaria . It highly effective adverse effect . The artemisinin component combine partner drug longer half-life ensure clearance remain parasite rapid reduction artemisinin . ACT use first-line treatment uncomplicated P. falciparum infection Indonesia since 2004 . There 3 combination available country include artesunate-amodiaquine ( AS-AQ ) , dihydroartemisinin-piperaquine ( DHA-PQ ) artemether-lumefantrine ( AL ) . Studies different site across Indonesia show various efficacy . Yet , increase concern reduce susceptibility P. falciparum artemisinin neighbour country . Therefore , need evaluate monitor efficacy combination Indonesia . Molecular marker important tool detect monitor presence antimalarial resistance . Their significant implication geographically map extent resistant-parasites , thus enable strategy control elimination apply inevitably increase disease burden occur . Different marker use identify antimalarial resistance recently molecular marker artemisinin susceptibility P. falciparum also propose . The presence marker parasite study also investigate .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>Male female All patient per 6 month age Fever define axillary temperature &gt; 37.5 C history fever 48 hour recruitment Infection P. falciparum detect microscopy Parasitaemia &gt; 250 /uL blood Ability swallow oral medication Ability willingness comply protocol duration study comply study visit schedule Informed consent patient parent guardian case child Absence history hypersensitive reaction contraindication antimalarial drug Not currently consume antibiotic antimalarial activity ( cotrimoxazole , macrolides , tetracycline doxycycline ) Presence general danger sign child 5 year sign severe falciparum malaria accord definition WHO ( 2000 ) Presence severe malnutrition accord WHO child growth standard Presence febrile condition cause disease malaria Presence severe anemia ( Hemoglobin &lt; 7 gr/dL ) Received study drug within past 4 week Received antimalarial within last 2 week Recurrent vomit ) necessitate single repeat dose ) Pregnant ( demonstrate positive result bHCG woman childbearing age Lactating mother</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>ACT</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>malaria</keyword>
	<keyword>efficacy</keyword>
	<keyword>Indonesia</keyword>
</DOC>